150 related articles for article (PubMed ID: 37077737)
1. Influence of chronic kidney disease and other risk factors pre-heart transplantation on malignancy incidence post-heart transplantation.
Roest S; Gürgöze MT; Cherikh WS; Stehlik J; Boersma EH; Zijlstra F; Manintveld OC
Front Cardiovasc Med; 2023; 10():1145996. PubMed ID: 37077737
[TBL] [Abstract][Full Text] [Related]
2. Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation.
Kim IC; Kim SH; Youn JC; Kim D; Lee S; Kim H; Kim JJ; Jung MH; Rossano JW; Cherikh WS; Kobashigawa JA; Stehlik J
JACC Heart Fail; 2024 Feb; 12(2):395-405. PubMed ID: 38326002
[TBL] [Abstract][Full Text] [Related]
3. Influence of renal insufficiency pre-heart transplantation on malignancy risk post-heart transplantation.
Roest S; Struijk C; Constantinescu AA; Caliskan K; Plasmeijer EI; Boersma E; Brugts JJ; Manintveld OC
ESC Heart Fail; 2021 Jun; 8(3):2172-2182. PubMed ID: 33779076
[TBL] [Abstract][Full Text] [Related]
4. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
5. Does recipient work status pre-transplant affect post-heart transplant survival? A United Network for Organ Sharing database review.
Ravi Y; Lella SK; Copeland LA; Zolfaghari K; Grady K; Emani S; Sai-Sudhakar CB
J Heart Lung Transplant; 2018 May; 37(5):604-610. PubMed ID: 29482932
[TBL] [Abstract][Full Text] [Related]
6. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
7. Association between infectious event and de novo malignancy after heart transplantation.
Bujo C; Amiya E; Hatano M; Tsuji M; Maki H; Ishida J; Ishii S; Narita K; Endo M; Ando M; Shimada S; Kinoshita O; Ono M; Komuro I
Heart Vessels; 2021 Apr; 36(4):499-508. PubMed ID: 33140148
[TBL] [Abstract][Full Text] [Related]
8. Age-Dependent Association Between Pre-transplant Blood Transfusion and Outcomes of Pediatric Heart Transplantation.
McKee C; Tumin D; Alevriadou BR; Nicol KK; Yates AR; Hayes D; Tobias JD
Pediatr Cardiol; 2018 Apr; 39(4):743-748. PubMed ID: 29340730
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation.
Vanderlaan RD; Manlhiot C; Edwards LB; Conway J; McCrindle BW; Dipchand AI
Pediatr Transplant; 2015 Dec; 19(8):896-905. PubMed ID: 26381803
[TBL] [Abstract][Full Text] [Related]
10. Early report from the Pediatric Heart Transplant Society on COVID-19 infections in pediatric heart transplant candidates and recipients.
Conway J; Auerbach SR; Richmond ME; Sharp B; Pahl E; Feingold B; Azeka E; Dryer WJ; Cantor RS; Kirklin JK;
J Heart Lung Transplant; 2022 Mar; 41(3):327-333. PubMed ID: 34903451
[TBL] [Abstract][Full Text] [Related]
11. Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: Analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database.
Karamlou T; Welke KF; McMullan DM; Cohen GA; Gelow J; Tibayan FA; Mudd JM; Slater MS; Song HK
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):456-461.e1. PubMed ID: 24183335
[TBL] [Abstract][Full Text] [Related]
12. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
13. Frequency and spectrum of metachronous malignancies in heart transplant recipients: a 11-year-experience at a German heart center.
Strecker T; Rösch J; Weyand M; Agaimy A
Int J Clin Exp Pathol; 2013; 6(3):411-20. PubMed ID: 23412350
[TBL] [Abstract][Full Text] [Related]
14. De novo malignancy in heart transplant recipients: A single center experience in Japan.
Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
[TBL] [Abstract][Full Text] [Related]
15. Impact of adult congenital heart disease on survival and mortality after heart transplantation.
Burchill LJ; Edwards LB; Dipchand AI; Stehlik J; Ross HJ
J Heart Lung Transplant; 2014 Nov; 33(11):1157-63. PubMed ID: 25049065
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
[TBL] [Abstract][Full Text] [Related]
17. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
18. Impact of using higher-risk donor hearts for candidates with pre-transplant mechanical circulatory support.
Han J; Moayedi Y; Yang W; Henricksen EJ; Lee R; Purewal S; Chang E; Duclos S; Lyapin A; Feng K; Hiesinger W; Teuteberg JJ; Khush KK
J Heart Lung Transplant; 2022 Feb; 41(2):237-243. PubMed ID: 34815161
[TBL] [Abstract][Full Text] [Related]
19. Trends in invasive disease due to Candida species following heart and lung transplantation.
Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant Type 2 Diabetes Mellitus Is Associated With Higher Graft Failure and Increased 5-Year Mortality After Heart Transplantation.
Rivinius R; Gralla C; Helmschrott M; Darche FF; Ehlermann P; Bruckner T; Sommer W; Warnecke G; Kopf S; Szendroedi J; Frey N; Kihm LP
Front Cardiovasc Med; 2022; 9():890359. PubMed ID: 35757347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
